Difference between revisions of "Teniposide (Vumon)"
m |
|||
| Line 18: | Line 18: | ||
*[http://chemocare.com/bio/teniposide.asp Teniposide (Vumon) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/teniposide.asp Teniposide (Vumon) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/bio/teniposide.asp Teniposide (Vumon) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/teniposide.asp Teniposide (Vumon) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/teniposide-patient-drug-information Teniposide (Vumon) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/teniposide-patient-drug-information Teniposide (Vumon) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/teniposide-patient-drug-information Teniposide (Vumon) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/teniposide-patient-drug-information Teniposide (Vumon) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | * 7/14/1992: Initial FDA approval | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Chemotherapy]] | ||
| + | [[Category:Irritant chemotherapy]] | ||
| + | [[Category:Topoisomerase inhibitors]] | ||
| + | |||
| + | [[Category:Acute lymphocytic leukemia medications]] | ||
| + | [[Category:Aggressive Non-Hodgkin lymphoma medications]] | ||
| + | [[Category:Central nervous system (CNS) cancer medications]] | ||
| + | [[Category:HIV-associated lymphoma medications]] | ||
| + | [[Category:Small cell lung cancer medications]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 1992]] | ||
Revision as of 14:42, 1 November 2014
Also known as VM-26.
General information
Class/mechanism: Topoisomerase II inhibitor. Teniposide inhibits type II topoisomerase, which results in single and double-stranded DNA breaks and DNA-protein crosslinks. It is cell-cycle specific, acting in late S or early G2, preventing cells from entering mitosis. It is dissolved in Cremophor EL (polyoxyethylated castor oil), which may cause hypersensitivity infusion reactions.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acute lymphocytic leukemia
- Aggressive Non-Hodgkin lymphoma
- Central nervous system (CNS) cancer
- HIV-associated lymphoma
- Small cell lung cancer
Patient drug information
- Teniposide (Vumon) patient drug information (Chemocare)[3]
- Teniposide (Vumon) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 7/14/1992: Initial FDA approval